Promising Alzheimer’s Drug Trial Results from Biogen

March 26th, 2015

Amyloid_plaques_alzheimer_disease_HE_stain crop2

Above: Amyloid plaques in the brain of an Alzheimer’s patient.

As reported recently in the New York Times (Business Day, March 20, 2015, “Biogen Reports Its Alzheimer’s Drug Sharply Slows Cognitive Decline”) and other media, the pharmaceutical company Biogen has announced impressive results in a Phase I “human safety” trial of a new drug designed to treat — and possibly prevent — Alzheimer’s disease. The drug, aducanumab, lowered brain Abeta levels and slowed decline in cognitive function compared to a control group of Alzheimer’s patients receiving a placebo.

Read more about these exciting results and what they mean for the future of Alzheimer’s drug development.